The Food and Drug Administration has approved Bavencio (avelumab; EMD Serono), a programmed death-ligand 1 (PD-L1) blocking antibody, in combination with Inlyta (axitinib; Pfizer), a kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Between 2007 to 2013, the incidence of metastatic PCa increased by 7.1% annually.
Early prostate cancer diagnosis rates fell, while cases of advanced prostate cancer remained stable.
An analysis of individual participant data from 15 prospective studies suggests a protective effect.
Some metastatic RCC patients may safely undergo surveillance prior to starting systematic therapy.
ADT for prostate cancer may be associated with a reduced risk of inflammatory bowel disease.
Ethnicity, education identified as factors that influence patients treatment decisions.
Prevalence of obesity is high in adults with a history of breast, prostate, or colorectal cancer.
External beam radiation therapy (EBRT) plus brachytherapy found to offer improved systemic control versus EBRT alone and radical prostatectomy.
Recurrent disease, second malignancy, late-onset treatment effects should be assessed in patients with new pain.
